Cryogenic and Regenerative Medicine Commercialization

by Alyssa Palmer, Sr. Supply Chain Consultant

Last week Cryoport, alongside McKesson, Fisher BioServices, and GE Healthcare, hosted the first annual two-day workshop Process Considerations for Cryogenic and Regenerative Medicine Commercialization. Cryoport is a provider of cold chain logistics solutions for bio-pharmaceutical, IVF, and animal health organizations around the world. This workshop provided a forum for industry experts to present and discuss current technology advancements in cryogenic management, regulatory requirements, and best practice processes in the support of regenerative medicine commercialization.  Alyssa Palmer, Sr. Supply Chain Consultant, represented Plaster Group at the workshop, and moderated a panel on regulatory guidelines.

Plaster Group is well-versed in the impact that efficient supply chains have on the healthcare sector and more importantly, the patient. Through partnerships with Seattle-based health focused organizations, Plaster Group has focused on implementing control towers across 16 countries to ensure better visibility throughout the health supply chain, better ensuring supply chain reliability and hopefully ensure that the medicines needed most arrive where they should. Our attendance at this workshop builds upon our foundation and goal to be a part of the future and availability of advancements in the new era of medicines: gene and cell-based products. As we continue to grow, and as the research and development for these new advancements move through the pipeline to commercialization, we anticipate a future of complex supply chain pathways; Plaster Group is there to help navigate them.

Plaster Group is Seattle based consulting firm built on the principle of local talent for local businesses. If you’re a local business looking to discuss further the challenges you are facing in an ever-changing Seattle we would love to hear from you!